Case Study

Model Extraction Studies Examined For Monoclonal Antibody In Prefilled Syringe (PFS)

Source: Nitto Avecia Pharma Services

By Aryo A. Nikopour

Model Extraction Studies Examined For Monoclonal Antibody In Prefilled Syringe (PFS)

It’s been more than 30 years since monoclonal antibodies were first licensed for clinical use.1

But product developers are still inventing novel ways to improve their safety and efficacy.

FDA approved Orthoclone OKT3 (muromonab-CD3) in 1986 for preventing kidney transplant rejection. As of March 2017, FDA has approved approximately 60 therapeutic monoclonal antibodies (MAbs), and many more are under evaluation in various phases of clinical trials.2

Supporting one of these MAbs, Nitto Avecia Pharma Services developed model extraction studies to evaluate the suitability of a glass prefilled syringe (PFS) for its intended use. The studies were designed to systematically examine the entire PFS assembly when exposed to a formulation buffer.

Monoclonal antibodies are nothing new. But product developers like Nitto Avecia Pharma Services are still inventing novel ways to improve them.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: